10-Q: AN2 Therapeutics Reports Q3 2025 Loss, Advances Pipeline

AN2 Therapeutics, Inc. reported a net loss of $9.35 million for Q3 2025, narrowing losses year-over-year, while advancing its Chagas disease and oncology programs.

Summary

• Reported a net loss of $9.35 million for the three months ended September 30, 2025, compared to a net loss of $12.75 million for the same period in 2024.
• Incurred a net loss of $26.46 million for the nine months ended September 30, 2025, a reduction from $43.80 million for the nine months ended September 30, 2024.
• Cash, cash equivalents, and investments totaled $65.1 million as of September 30, 2025.
• Management believes current cash, cash equivalents, and investments are sufficient to fund operations for at least 12 months from the filing date.
• Research and development expenses decreased to $7.0 million for Q3 2025 from $8.29 million for Q3 2024, and to $17.89 million for the nine months ended September 30, 2025, from $35.09 million for the same period in 2024.
• Initiated Phase 1 start-up activities for AN2-502998 (Chagas disease) in May 2025 and completed dosing the first Single Ascending Dose cohort in August 2025.
• Discontinued development of epetraborole for treatment-refractory MAC lung disease in May 2025 after the truncated Phase 3 portion of the EBO-301 study did not meet its primary endpoint.
• The NIAID contract funding for the melioidosis program was reduced by $9.0 million to a cumulative total of $9.3 million in June 2025 due to a U.S. government cost efficiency initiative.
• Material weaknesses in internal control over financial reporting, previously identified, continue to exist as of September 30, 2025.

Sentiment

Score: 4

Explanation: The company reported narrowed net losses and is advancing several early-to-mid-stage pipeline candidates in areas of high unmet medical need. However, the significant setback of discontinuing a Phase 3 program (MAC lung disease) due to failure, coupled with a substantial reduction in government funding and persistent material weaknesses in internal controls, indicates significant challenges. The 12-month cash runway also highlights an imminent need for further capital, which will likely lead to dilution.

Positives

• Net loss for Q3 2025 narrowed to $9.35 million from $12.75 million in Q3 2024, and for the nine months to $26.46 million from $43.80 million in 2024.
• Cash, cash equivalents, and investments of $65.1 million are projected to fund operations for at least 12 months.
• Advanced AN2-502998 for chronic Chagas disease into Phase 1 clinical trials, with the first Single Ascending Dose cohort successfully dosed.
• Established a collaboration with Drugs for Neglected Diseases initiative (DNDi) to accelerate clinical development of AN2-502998.
• Anticipates advancing the first oncology compound into development in early 2026, with potential clinical proof-of-concept data within the current cash runway.
• Expects to advance a second oncology compound into development in mid-2026.
• Supporting the design of an investigator-initiated trial (IIT) for epetraborole in M. abscessus lung disease, with enrollment expected to begin in early 2026.
• Completed enrollment in a 200-patient observational trial for acute melioidosis in October 2024 and announced key insights in June 2025, optimizing future clinical study design.

Negatives

• Discontinued development of epetraborole for treatment-refractory MAC lung disease following the failure of the Phase 3 portion of the EBO-301 study to meet its primary endpoint.
• NIAID contract funding for the melioidosis program was reduced by $9.0 million to a cumulative total of $9.3 million due to a U.S. government cost efficiency initiative.
• Continued to incur significant operating losses, with an accumulated deficit of $232.2 million as of September 30, 2025.
• Material weaknesses in internal control over financial reporting persist, indicating a risk of inaccurate or untimely financial reporting.
• Interest income decreased by $0.6 million for Q3 2025 and $2.1 million for the nine months ended September 30, 2025, primarily due to lower cash and investment balances and lower interest rates.

Risks

• Limited operating history and no products approved for commercial sale; may never achieve or maintain profitability.
• Pipeline is primarily early-stage and mid-stage, with no clinical proof of concept yet established for any product candidates.
• Requires substantial additional funding; inability to raise capital could force delays or cessation of development programs or commercialization efforts.
• Clinical trials of product candidates may fail to demonstrate safety and/or efficacy, leading to additional costs or delays.
• Potential for delays or difficulties in patient enrollment for clinical trials, especially for rare diseases like Chagas.
• Reliance on single-source third parties (CROs, CMOs) for preclinical studies, clinical trials, and manufacturing increases risks of delays or insufficient supplies.
• Even if regulatory approval is obtained, product candidates may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Faces substantial competition from major pharmaceutical and biotechnology companies with greater resources.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel, operating with a small team.
• Material weaknesses in internal control over financial reporting could lead to inaccurate or untimely financial reporting.
• Rights to develop and commercialize technology and product candidates are subject to license agreements; failure to comply could result in loss of rights.
• Inability to obtain and maintain patent and other intellectual property protection, or if protection is not sufficiently broad, competitors could develop similar products.
• May not realize expected benefits from the August 2024 business restructuring and workforce reduction, potentially incurring additional costs or difficulties.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit commercial potential.
• Inability to protect the confidentiality of proprietary information, know-how, and trade secrets could harm business and competitive position.
• Failure to obtain patent term extension and data exclusivity for product candidates could materially harm the business.
• Non-compliance with government patent agency requirements could reduce or eliminate patent protection.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker intellectual property laws.
• Potential involvement in lawsuits to protect or enforce owned or in-licensed patents or other intellectual property, which could be expensive and time-consuming.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights, leading to uncertain outcomes and potential harm to the business.
• Subject to claims by third parties asserting misappropriation of intellectual property rights or claiming ownership of company's intellectual property.
• Trademarks may be infringed or successfully challenged, harming the business.
• Significant disruptions of information technology systems or cybersecurity incidents could result in financial, legal, regulatory, business, and reputational harm.
• Subject to U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.
• Concentration of ownership of common stock among existing executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• Sales of a substantial number of shares of common stock may cause the price of common stock to decline.
• Provisions in corporate charter documents and under Delaware law, and the adoption of a rights plan, could make an acquisition of the company more difficult.
• Broad discretion in the use of cash, which may be invested or spent in ways stockholders do not agree with.
• No anticipation of paying cash dividends in the foreseeable future; stockholders must rely on capital appreciation.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• The trading price of common stock has been and may continue to be volatile.
• Incurring significantly increased costs as a public company, with management devoting substantial time to new compliance initiatives.
• As an emerging growth company, reduced disclosure and governance requirements may make common stock less attractive to investors.
• Failure to adhere to the listing requirements of the Nasdaq Global Select Market could result in delisting.
• Recent and potential future changes to U.S. and non-U.S. tax laws could materially adversely affect the company.
• Indemnity provisions in various agreements potentially expose the company to substantial liability for intellectual property infringement, data protection, and other losses.

Future Outlook

The company anticipates Phase 1 data for AN2-502998 (Chagas disease) in Q1 2026 and expects to initiate a Phase 2 proof-of-concept study in patients with chronic Chagas disease in 2026. It also plans to advance its first oncology compound into development in early 2026, with potential clinical proof-of-concept data within the current cash runway, and a second oncology compound in mid-2026. An investigator-initiated trial for epetraborole in M. abscessus lung disease is expected to begin enrollment in early 2026, and discussions are ongoing with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis. Operating expenses are expected to increase significantly as product candidates advance through development, regulatory approval, and potential commercialization, necessitating future financing through equity, debt, or collaborations.

Management Comments

• "We are committed to delivering high-impact drugs to patients that address critical medical needs and improve health outcomes."
• "Management believes that its cash, cash equivalents, and investments as of September 30, 2025 will be sufficient to fund its current operating plan through at least 12 months from the issuance date of these condensed financial statements."
• "With the completion of pivotal work under the contract, including the manufacture of drug product, the Company is engaged with federal agencies to fund a Phase 2 proof-of-concept clinical trial for acute melioidosis."
• "We anticipate Phase 1 data in the first quarter of 2026 and initiation of a Phase 2 proof-of-concept study in patients with chronic Chagas disease in 2026, depending on the outcome and timing of completion of the Phase 1 study."
• "We anticipate advancing the first oncology compound into development in early 2026 with potential clinical proof-of-concept data within the Company’s current cash runway."
• "We expect to advance our second oncology compound into development in mid-2026."
• "The Company is supporting the design of an investigator-initiated trial (IIT) expected to begin enrollment in early 2026, pending finalization of the trial protocol and regulatory allowance to proceed."
• "The aim of the program [melioidosis] is to meaningfully lower the expected mortality rate by dosing epetraborole on top of SOC."

Industry Context

AN2 Therapeutics operates as a biopharmaceutical company leveraging its boron chemistry platform to discover and develop novel small molecule therapeutics. The company focuses on areas with high unmet medical needs, including Chagas disease, non-tuberculous mycobacterial (NTM) lung disease caused by M. abscessus, melioidosis, and oncology. The filing highlights the absence of FDA-approved treatments for chronic Chagas disease and M. abscessus lung disease, underscoring the significant market opportunity if its candidates succeed. Melioidosis is noted as a highly lethal bacterial infection with a high mortality rate despite current standard of care, indicating a critical need for improved therapies. The company's boron chemistry approach is positioned as offering competitive advantages in binding-site differentiation and drug-like properties, having produced first-in-class molecules against specific targets.

Comparison to Industry Standards

• AN2-502998 is noted as the only compound known to have demonstrated curative activity in preclinical studies across multiple species, including non-human primates with long-term, naturally acquired chronic infections of diverse T. cruzi genetic types, suggesting a potentially differentiated profile in Chagas disease compared to other preclinical or early-stage candidates.
• The company targets M. abscessus lung disease, for which no FDA-approved therapies exist, positioning its epetraborole program against a high unmet medical need rather than direct competition with approved drugs.
• For acute melioidosis, the program aims to meaningfully lower the 90-day mortality rate, which approaches 40% despite standard of care drugs like ceftazidime or meropenem, setting a high bar for clinical improvement against existing treatments.

Corporate Governance

Legal Proceedings

• The company was not subject to any material legal proceedings as of September 30, 2025, and December 31, 2024, and is not currently a party to any legal proceeding expected to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• During the nine months ended September 30, 2025, an existing stockholder participated in the pre-funded warrant transaction, exchanging 2,952,000 shares of common stock for warrants.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and continued stock price volatility due to ongoing losses and development risks, but also potential upside from pipeline advancements.
• Employees experienced a workforce reduction of approximately 50% in August 2024, which may impact morale and increase workload for remaining staff.
• Patients in need of treatments for Chagas disease, M. abscessus lung disease, melioidosis, and oncology targets may benefit from the company's ongoing development programs, but the discontinuation of the MAC lung disease program eliminates a potential treatment option.
• Creditors and suppliers face risks associated with the company's continued operating losses and reliance on future financing, although current cash is projected to last for at least 12 months.

Next Steps

• Anticipate Phase 1 data for AN2-502998 in Q1 2026.
• Anticipate initiation of a Phase 2 proof-of-concept study for AN2-502998 in patients with chronic Chagas disease in 2026.
• Advance the first oncology compound into development in early 2026.
• Advance the second oncology compound into development in mid-2026.
• Begin enrollment in an investigator-initiated trial (IIT) for epetraborole in M. abscessus lung disease in early 2026.
• Engage with federal agencies to fund a Phase 2 proof-of-concept clinical trial for acute melioidosis.
• Continue efforts to remediate material weaknesses in internal control over financial reporting.
• Seek additional funding through equity offerings, debt financings, or collaborations to support future operations.

Key Dates

Recommendation

While AN2 Therapeutics has narrowed its net losses and is advancing several promising early-to-mid-stage pipeline candidates in areas of high unmet medical need (Chagas, oncology, melioidosis), the recent failure and discontinuation of its Phase 3 MAC lung disease program is a significant setback. The reduction in NIAID funding and persistent material weaknesses in internal controls also raise concerns. The company's cash runway is estimated at 12 months, necessitating future capital raises which will likely cause further shareholder dilution. Given the early stage of most programs and the inherent high risks of biopharmaceutical development, a "Hold" recommendation is appropriate. Investors should monitor progress in the Chagas and oncology programs, as well as the company's ability to secure additional non-dilutive funding and address internal control deficiencies, before considering further investment.

Keywords

Biopharmaceutical, Boron Chemistry, Chagas Disease, NTM Lung Disease, M. abscessus, Melioidosis, Oncology, Drug Development, Clinical Trials, SEC Filing, 10-Q, AN2 Therapeutics, ANTX, Rare Disease, Infectious Disease, Intellectual Property, Corporate Governance, Financial Reporting